Tetrahedron Letters
Stereoselective synthesis of the C21–C29 fragment of (+)-Sorangicin A
employing iodocyclization reactions
⇑
Debendra K. Mohapatra , Shivalal Banoth, Jhillu S. Yadav
Natural Products Chemistry Division, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India
Academy of Scientific and Innovative Research, New Delhi 110001, India
a r t i c l e i n f o
a b s t r a c t
Article history:
A stereoselective synthesis of the C21–C29 fragment of (+)-Sorangicin A has been described following our
recently developed iodine-catalyzed tandem isomerization followed by C–O and C–C bond formation for
the construction of trans-2,6-disubstituted dihydropyran as the key step. In this Letter, the problem of
installing the C25 asymmetric center has been sorted out by utilizing an iodolactonization strategy.
Ó 2015 Elsevier Ltd. All rights reserved.
Received 26 August 2015
Revised 11 September 2015
Accepted 13 September 2015
Available online 14 September 2015
Keywords:
Natural products
Iodocyclization
trans-2,6-Disubstituted dihydropyran
Isomerization
Asymmetric a-aminoxylation of aldehyde
Introduction
groups, with only total synthesis from Smith and co-workers9
and a formal synthesis from Crimmins and co-workers.10 As part
Antibiotics have been used to fight against infectious disease
caused by bacteria and other microbes. Antibacterial chemother-
apy has been a leading cause for the dramatic rise of average life
expectancy. However, in a world of ever-increasing antibiotic
resistance, the discovery and development of new, potent antibi-
otics are of utmost importance. The secondary metabolite (+)-Sor-
angicin A (1) was isolated by Höfle and co-worker1 in 1985 from
the gliding myxobacteria Sporangium cellulosum. This shows
extraordinary antibiotic activity against a broad panel of both
Gram-positive (MIC value of average 10 ng/mL) and Gram-negative
of our ongoing research on total synthesis of complex natural prod-
ucts11 following our own developed protocol of tandem isomeriza-
tion followed by C–O and C–C bond formation reaction leading to
trans-2,6-disubstituted dihydropyran, we have recently reported
the synthesis of C28–C37 fragment of Sorangicin A.12
In continuation of our effort toward the total synthesis of
Sorangicin A, herein, we describe our successful attempt on the
synthesis of the C21–C29 fragment and installation of the C25
hydroxyl by employing iodocyclization and base-induced isomer-
ization strategy.
bacteria (MIC value of average 10 l
g/mL).2 The mechanism of
action was subsequently determined to entail inhibition of RNA
polymerase in both Escherichia coli and Staphylococcus aureus with-
out affecting the eukaryotic cells.2 In addition, Sorangicin A is
active in vitro against several cancer cell lines.3 The structure of
Sorangicin A contains 31-membered macrocyclic lactone with
C1–C8 carboxylic acid side Chain and 15 stereogenic centers, and
was secured by X-ray crystallographic techniques. Owing to its
potent antibiotic activity and architectural complexity, the stereos-
elective total synthesis of Sorangicin A (1) has attracted consider-
able interest from a number of groups including pioneering
studies from Morken,4 Scinzer,5 Lee,6 Yadav,7 and Hong8 research
Results and discussion
The retrosynthetic route to C21–C29 fragment 2 of (+)-Sorangi-
cin A is presented in Scheme 1. For the stereoselective introduction
of the C22 hydroxyl group, we planned to perform an organocat-
alytic
a
-carbonyl oxidation using MacMillan’s protocol13 to the
aldehyde which would be obtained from compound 5 by following
Jin’s oxidative strategy.14 The functionalized pyran 5 could be
formed by 6-exo trig iodolactonization reaction of the correspond-
ing acid 6. The required precursor 7 in turn would be synthesized
from d-hydroxy
a,b-unsaturated aldehyde 8, which in turn could
be accessed from commercially available 1,3-propanediol (9).
Synthesis of trans-2,6-disubstituted-3,4-dihydropyran 7 began
with 1,3-propane diol 9 as detailed in (Scheme 2). Accordingly by
⇑
Corresponding author. Tel.: +91 40 2719 3128; fax: +91 40 2716 0512.
0040-4039/Ó 2015 Elsevier Ltd. All rights reserved.